BTG3 and COVID-19: No significant differences were observed in positive ANA titer between total COVID-19 patients, controls, and IMV controls (p=0.272), or between COVID-19 patients with favorable (n=37; 29%) and unfavorable disease course (n=33; 27%) (p= 0.842).